Abstract

BackgroundTo determine the diagnostic accuracy of major salivary gland ultrasonography (SGUS) in primary Sjögren’s syndrome (pSS) using the novel Outcome Measures in Rheumatology Clinical Trials (OMERACT) scoring system in a large-scale multicentre study.MethodsSGUS was conducted for 246 pSS patients, 140 control subjects with conditions other than SS and 27 healthy control subjects. The echostructure features from the parotid and submandibular glands on both sides were graded using the novel OMERACT scoring system. Receiver operating characteristic curves were used to describe the diagnostic accuracy of the scoring system for pSS. The associations between the SGUS and disease characteristics were analysed to evaluate the clinical value of SGUS for pSS.ResultsThe US scores in the pSS group were significantly higher than those in the non-pSS group (p < 0.001). The level of diagnostic accuracy was comparable with the scores of all four glands (AUC=0.908) when only the parotid and submandibular glands on either side were scored (AUC=0.910, 0.904, respectively). The optimal cut-off value for the left (right) parotid gland and the left (right) submandibular gland was 4, with maximal sensitivity (75.6% and 77.2%, respectively) and specificity (91.6% and 92.2%, respectively). The pSS patients with positive SGUS results presented a longer disease duration, parotid enlargement, dental loss and higher levels of serological markers, such as anti-SSA, anti-SSB, positive RF, IgG and γ-globulin%.ConclusionsSGUS with the OMERACT scoring system yields high sensitivity and specificity, demonstrating high diagnostic feasibility for pSS. The SGUS may have implications for deciding disease severity and treatment efficacy.

Highlights

  • To determine the diagnostic accuracy of major salivary gland ultrasonography (SGUS) in primary Sjögren’s syndrome using the novel Outcome Measures in Rheumatology Clinical Trials (OMERACT) scoring system in a large-scale multicentre study

  • The control group comprised a total of 167 subjects: 113 non-s syndrome (SS) patients with various rheumatic diseases (29 with undifferentiated connective tissue disease, 32 with connective tissue disease, 2 with mixed connective tissue disease, 28 with rheumatoid arthritis, 13 with systemic lupus erythematosus, 1 with sclerosis, 1 with systemic vasculitis, 7 with primary biliary cirrhosis), 27 with idiopathic Sicca syndrome and 27 healthy subjects (female/male ratio 156/11; age 51.21 (S.D. 13.72) years)

  • Features of SGUS in primary Sjögren’s syndrome (pSS) All patients and control group underwent SGUS scores which displayed no difference between bilateral parotid glands (p =0.798), followed by bilateral submandibular glands (p=0.842)

Read more

Summary

Introduction

To determine the diagnostic accuracy of major salivary gland ultrasonography (SGUS) in primary Sjögren’s syndrome (pSS) using the novel Outcome Measures in Rheumatology Clinical Trials (OMERACT) scoring system in a large-scale multicentre study. There have existed various imaging techniques in assessing the involvement of salivary glands in individuals with Sjögren’s syndrome (SS). Considering that these techniques are mostly invasive and. To standardize SGUS, the Outcome Measures in Rheumatology Clinical Trials (OMERACT) working group has reached an international expert consensus on SGUS elementary lesion definitions and a novel fourgrade semiquantitative scoring system (grade 0–3) for pSS [10]. The diagnostic accuracy and feasibility for pSS and non-pSS sicca patients remain to be tested in clinical practice in large cohort studies

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call